NEW YORK, Dec. 3 – DNAPrint Genomics of Sarasota, Fla., said Monday that it had entered an agreement with the New York University School of Medicine to identify genetic markers that can help determine how recipients of kidney transplants will respond to certain drugs.
Under the terms of the deal, NYU's Mary Lea Johnson Richards Organ Transplantation Center will provide DNAPrint with patient samples and clinical data from patients. DNAPrint will use its genotyping technologies and SNP database to screen the specimens for markers.
“The goal of the project is to identify pharmacogenomic classifiers that could be used to match renal transplantation patients with the optimal immunosuppressant for their genetic architecture,” DNAPrint said in a statement.
The company estimated that the project would take about one year to complete.
Financial terms of the deal were not disclosed.
In August, DNAPrint Genomics announced a deal to study specimens provided by Pharsight of Mountain View, Calif., to determine which genetic markers are responsible for patients' varying responses to drugs designed to treat metabolic disorders.